AppliChem, located in Darmstadt, Germany, and Akron Biotech, based in Florida, USA are merging forces for the manufacturing and distribution of both companies' products. Commencing March 2, Akron is taking over AppliChem's operations in the Americas and will be called AppliChem LLC. AppliChem says it is committed to offering its customers the same high-quality products including animal serum, recombinant proteins, serum-free media and other cell-culture components in addition to AppliChem's full list of 4,000 products such as amino acids and powder media. The merger will allow them to expand product offering dramatically and accelerate growth, notes Akron.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze